

2019-2023 Competing in the UK Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

https://marketpublishers.com/r/2545E29C81FEN.html

Date: March 2019

Pages: 565

Price: US\$ 4,850.00 (Single User License)

ID: 2545E29C81FEN

Abstracts

LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant



market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests—Over 200 current and emerging assays including:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals

Commercial/Private Laboratories

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products



Review of over 200 current and emerging cancer diagnostic tests, including: Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.



Contains 565 pages and 85 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

- 1. Market Overview
- 2. Worldwide Market Structure
- 3. Worldwide Market Size and Growth

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology



- 1. Breast Cancer
- 2. Lung Cancer
- 3. Colon and Rectum Cancer
- 4. Prostate Cancer
- 5. Stomach Cancer
- 6. Leukemia
- 7. Lymphoma
- 8. Oral Cancer
- 9. Skin Cancer
- 10. Uterine Cancer
- 11. Ovarian Cancer
- 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16.
 - 23. TdT
 - 24. Thyroglobulin
 - 25. Tissue Polypeptide Antigen (TPA)
 - 26. Biochemical Tumor Markers
 - 27. Oncogenes

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44



	for	
\cup	-108	Ó

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine



Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA 50

CA 72-4/TAG-72

CA 195

CA-242

CA-549

CAM 26

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA



HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA 93

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma 552

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor 1

Myosin

NEA-130

NMP22

OA-519

Opioid Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL 175

Selectin

Sialic Acid



Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG 12

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - 3. Molecular Diagnostics
 - 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. Artificial Intelligence
 - 6. Flow Cytometry
 - 7. Two Dimensional Gel Electrophoresis (2-DGE)
 - 8. Biosensors
 - 9. Competing/Complementing Technologies
- E. Personal Testing

VIII. UK CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- **B.** Business Environment
- C. Market Structure
- D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier



Sales and Market Shares by Test

IX. COMPETITIVE PROFILES

Abbott

AdnaGen/Alere

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode Genetics

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Elitech Group

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco



PreMD

Qiagen

Quest Diagnostics

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Thermo

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS



List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast by Market Segment

U.K., Estimated Cancer Death Rates Per 100,00 Population

U.K., Laboratories Performing Tumor Marker Tests by Market Segment

U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume



- U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
- U.K., All Market Segments Major Tumor Marker Test Volume Forecast
- U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
- U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
- U.K., Total Tumor Marker Sales Forecast by Market Segment
- U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
- U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Colon-Specific Antigen Test Volume And Diagnostics Sales by Market Segment
- U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment



- U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., S-10 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Total Tumor Marker Sales and Market Shares Forecast
- U.K., CEA Testing Market Diagnostics Sales by Major Supplier
- U.K., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2019-2023 Competing in the UK Cancer Diagnostics Market: Supplier Shares and Sales

Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies,

Instrumentation and Opportunities

Product link: https://marketpublishers.com/r/2545E29C81FEN.html

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2545E29C81FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970